ArticleJournal of oral & facial pain and headache2025
Antinociceptive and anti-inflammatory effects of a formulation based on
Article in Journal of oral & facial pain and headache, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent pharmacological treatments for acute orofacial pain present limitations, risks, and side effects. Thus, the search for safer alternatives is justified. The essential oil of
methodsAdult male Wistar rats were subjected to intraoral incision surgery, a model of postoperative pain. The effect of the facial topical application (1 to 3 times a day for 3 days) of EOAz or a formulation based on EOAz (Fb-EOAz) was assessed on heat and mechanical hyperalgesia. The same rats were tested in the open field test (OFT) to assess the influence of the treatments on rats' locomotion. Moreover, the effects of the treatments were evaluated on facial heat hyperalgesia induced by lipopolysaccharide (LPS), a model of myofascial pain, and
resultsEOAz and Fb-EOAz reduced postoperative heat hyperalgesia, but only Fb-EOAz reduced postoperative mechanical hyperalgesia and heat hyperalgesia induced by LPS. Fb-EOAz reduced NO and interleukin-6 release by macrophages stimulated by LPS. None of the treatments affected the rat's locomotion.
conclusionsThese data provide preclinical evidence of antinociceptive and anti-inflammatory effects of Fb-EOAz. This approach may represent an alternative or adjuvant therapy in the control of inflammatory and myofascial orofacial pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.